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and Ortonne, 2012; Richmond et al.,
2013). Future studies may reveal how
“abnormal” melanocytes promote auto-
immunity in vitiligo, and speciﬁcally
how CXCL10 is initially induced in
disease.
Targeted therapy may
promote repigmentation
in vitiligo by serving as
the ‘WNT beneath the
wings’ of regenerating
melanocytes.
The study by Regazzetti et al. (2015)
conﬁrms our ﬁndings that CXCL10 is
expressed within active lesional skin in
vitiligo (Rashighi et al., 2014), and,
further, it suggests that subtle inﬂamma-
tion is ongoing in even normally pig-
mented skin. In addition, this study
connects oxidative stress in melano-
cytes to the WNT signaling pathway,
revealing that intrinsic defects in
melanocytes from such patients likely
include impaired WNT signaling.
Finally, the authors hypothesize that
pharmacological activation of the
pathway could help promote melano-
cyte differentiation and repigmentation
during treatment, serving as the “WNT
beneath the wings” of regenerating
melanocytes, which must go through a
series of steps, beginning with differ-
entiation of melanocyte precursors in
the hair follicles or other niches of the
skin and then progressing through prolife-
ration, migration, and further differentia-
tion into functional melanocytes. The
study used an innovative new ex vivo
vitiligo skin culture model to demonstrate
that WNT activators begin this process by
differentiating melanoblasts but, because
of the limited time that the cultures could
be maintained ex vivo, the authors were
unable to determine whether this would
progress to promote fully functional
melanocytes. The role of WNT signal-
ing in events downstream of melano-
cyte differentiation is not clear, and future
studies will hopefully to assess this in
order to translate these results into new
treatments.
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Microenvironment-Driven Resistance
to BRAF Inhibition Comes of Age
Dinoop Ravindran Menon1 and Helmut Schaider1,2
Increasingly comprehensive observations indicate that the tumor microenviron-
ment contributes to drug resistance toward small molecule inhibitors. Fedorenko
et al. describe a role for ﬁbroblasts in creating a favorable niche for melanoma
cell survival if treated with the BRAF inhibitor vemurafenib. TGF-β released by
vemurafenib-treated melanoma cells stimulated ﬁbroblasts for increased
α-smooth muscle actin, neuregulin (NRG), and ﬁbronectin expression.
Off-target effects of vemurafenib led to paradoxical secretion of hepatocyte
growth factor (HGF) by ﬁbroblasts. Combined inhibition of BRAF/MET/HER
kinases was insufﬁcient to reverse the protective effect of the ﬁbroblasts,
whereas reversal was achieved by combined BRAF/PI3K inhibition. A thorough
understanding of the complex spatiotemporal interactions in tumor microenvir-
onments holds promise for improved targeting using combination therapies in
patients with melanoma.
Journal of Investigative Dermatology (2015) 135, 2923–2925. doi:10.1038/jid.2015.373
Small molecule inhibitors have brought
about a strategic shift in the way
melanomas are treated. Melanoma
patients harboring BRAF mutations in
particular have reaped signiﬁcant beneﬁt
from small molecule BRAF–MEK
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inhibitor combination therapy. How-
ever, after initial rapid tumor regression,
recurrences have been observed in
almost all patients. There have been
many studies depicting the importance
of gene ampliﬁcation and mutation that
explain a Darwinian model of acquired
drug resistance against BRAF–MEK
inhibitors. However, recent evidence
points to an equally important role of
symbiotic interaction of cancer cells
with their microenvironments in
facilitating the development of drug
resistance.
The initial observation that extrinsic
factors from the microenvironment may
contribute to drug resistance in cancer
was published by Straussman et al.,
depicting the importance of hepatocyte
growth factor (HGF) secreted by stromal
cells, particularly ﬁbroblasts, in
mediating resistance toward BRAF
inhibitors through the activation of the
MET, MAPK, and Pi3K-AKT pathways
(Straussman et al., 2012). However, the
impact of extracellular matrix (ECM)
and adhesion molecules on conferring
resistance to BRAF–MEK inhibitors
remained elusive until the recent
publications by Hirata et al. (2015)
and Fedorenko et al. (2015a,b). Hirata
et al., described the paradoxical
activation of the BRAF-ERK pathway in
ﬁbroblasts by BRAF inhibition, which
was partially directed through the
expression of PDGFR-α. They reported
that this activation leads to the secretion
of ECM proteins, such as ﬁbronectin
and tenascin-C, which contributed to
matrix stiffness and which in turn,
induced remodeling of integrin β1 and
focal adhesion kinase (FAK) phosphor-
ylation. FAK phosphorylation was
shown to reactivate ERK phosphoryla-
tion independently of BRAF inhibition
in melanoma cells, contributing to
resistance. Importantly, ERK activity
was lowered in BRAF resistant cells
by addition of a MEK inhibitor
re-sensitizing melanoma spheroids
co-cultured with ﬁbroblasts. In
long-term survival data, combined
BRAF–MEK inhibition has been
reported to increase overall survival in
BRAF-mutant melanoma patients
(Smalley and Sondak, 2015).
The new study by Fedorenko et al.
brings together the several modes of
symbiotic interaction between ﬁbro-
blasts in the tumor microenvironment
and melanoma cells to establish a
holistic view of microenvironment-
mediated drug resistance. In response
to BRAF inhibition, melanoma cells
secrete TGF-β, inducing activation of
ﬁbroblasts and secretion of ﬁbronectin.
This melanoma cell-mediated phenom-
enon appears to act in concert with
paradoxical activation of ﬁbroblasts by
the BRAF inhibition itself. Although
paradoxical activation of the ERK
pathway by BRAF inhibition contributes
to HGF secretion in ﬁbroblasts,
melanoma-derived TGF-β induced
the expression of neuregulin (NRG),
which has been reported to promote
resistance toward BRAF/MEK inhibitors.
The direct effect of TGF-β signaling in
melanoma cells in conferring resistance
to BRAF–MEK inhibitors seems to be
cell speciﬁc and context dependent, as
there are reports that suggest this
signaling to either sensitize the cells
(Smith et al., 2013; Menon et al., 2013)
or induce resistance (Sun et al., 2014).
Either way, this non-cell-autonomous
effect of TGF β could be having
a far more signiﬁcant role in the context
of the tumor microenvironment
than direct cellular effects on
melanoma cells.
Fedorenko et al. show further that
upregulation of ﬁbronectin secretion
promotes signaling through multiple
RTKs by affecting their phosphorylation,
following treatment with their respec-
tive ligands. Knockdown of ﬁbronectin
reduced the extent of MET phosphory-
lation after exposure to HGF, EGFR
phosphorylation following EGF treat-
ment, and HER3 phosphorylation after
NRG exposure. All these pathways
affected both ERK and Pi3K/AKT signal-
ing directly, traditionally acknowledged
as contributing signiﬁcantly to BRAF
inhibitor resistance. Accordingly, block-
ing any one of these receptors with
speciﬁc small molecule inhibitors, in
combination with BRAF inhibitors, was
found to have only limited effects in
reducing AKT signaling, suggesting that
each pathway contributes only partially
to overall signaling recovery. Direct
inhibition of Pi3K with speciﬁc
inhibitors was observed to be more
effective at inducing apoptosis in
co-cultures and in a murine model.
These observations are of great
importance toward understanding the
multiple modes of interaction between
melanoma cells and their micro-
environments, and they may lead to
improved therapeutic strategies.
Melanoma cell ﬁbroblast
remodeling of the tumor
microenvironment
facilitates therapeutic
escape from BRAF
inhibition.
Recent studies suggest that melanoma
cells themselves could be phenocopy-
ing and mimicking certain aspects of
this interaction, even in the absence of
ﬁbroblasts, to induce drug resistance.
In a recent publication, Fedorenko et al.
show that PTEN-null melanoma cells
secrete ﬁbronectin when exposed to
BRAF inhibitors or other chemothera-
peutic agents, leading to upregulated
Pi3K/AKT signaling and sustained Mcl-1
levels via integrin α5/β1 (Fedorenko
et al. (2015a,b)). This ﬁnding corres-
ponds with the report of Hirata et al.,
2015, who intriguingly have also
demonstrated a role for integrin β1 in
mediating ﬁbronectin-induced resis-
tance through the FAK-src axis.
Whereas Fedorenko et al. focused on
the activation of AKT signaling, Hirata
et al. described ERK activation, thereby
implying that signaling leads to activa-
tion of both pathways. Accordingly, our
own group has reported that melanoma
cells are able to establish an innate
response to chronic stress that leads to
an intrinsic phenotypic shift. This shift is
characterized by activation of multiple
receptor tyrosine kinases, leading to
FAK-src signaling activation, and
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culminating in hyperactivation of both
AKT and ERK signaling, ultimately
leading to multiple-drug tolerance
(Menon et al., 2015). Together, these
timely observations suggest that
melanoma cells are capable of co-
opting the microenvironment to their
advantage by either symbiotic interac-
tions with ﬁbroblasts or by directly
phenocopying certain aspects of differ-
entiated cells such as ﬁbroblasts. This
includes the secretion of ﬁbronectin and
other ECM proteins to create a permis-
sible environment for surviving drug
exposure. Targeting these interactions
may be useful for more effective disease
management.
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